48 results about "Chorioallantoic membrane" patented technology

The invention belongs to the technical field of tumor treatment, and particularly relates to a synthetic peptide NK3R-A1 based on an NK3 receptor. The synthetic peptide NK3R-A1 based on the NK3 receptor has the tumor angiogenesis resisting effect. The molecular weight of the synthetic peptide is 1330.46, and the specific sequence of the synthetic peptide is NGRGGDFF(MeF)GLM-NH2. The synthetic peptide is prepared through an Fmoc solid-phase polypeptide synthesis method and can be used for preparing anti-tumor preparations. Through in-vitro cell viability experiments, cell scratch experiments and cell migration experiments, the angiogenesis resisting effect of the synthetic peptide is verified; meanwhile, through further chicken chorioallantoic membrane carrier experiments and euangiotic mice S180 transplantation tumor model experiments on the synthetic peptide, it is verified that the synthetic peptide is obvious in tumor inhibiting effect, has the tumor angiogenesis resisting effect and has no obvious toxic or side effect; the synthetic peptide has good medical application prospects and also provides a targeting sequence with great potential for tumor treatment.